Skip to main content
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. — Investor Relations & Filings

Ticker · JSPR ISIN · US4718712023 US Professional, scientific and technical activities
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-06-07 Merger & Acquisition
Country US United States of America
Listing US JSPR

About Jasper Therapeutics, Inc.

https://jaspertx.com/

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
REGISTRATION STATEMENT
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, dated June 7, 2021. It includes a proxy statement/prospectus related to a Business Combination (merger) between Amplitude Healthcare Acquisition Corporation and Jasper Therapeutics, Inc. The document contains detailed information about the merger agreement, stockholder voting, and securities registration for the transaction. This type of filing is specifically related to merger and acquisition activity and tender offers, as indicated by the Form S-4 and the detailed merger terms. It is not an annual report, earnings release, or other financial report, but a regulatory filing for a merger transaction. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (15,000 characters) and content confirm it is the actual filing, not just an announcement or certification.
2021-06-07 English
425 Filing
Regulatory Filings
2021-06-01 English
425 Filing
Regulatory Filings
2021-05-26 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2021
2021-05-24 English
AMENDMENT NO. 1 TO FORM 10-K
Annual Report FY 2020
2021-05-24 English
425 Filing
Regulatory Filings
2021-05-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.